Alpha 2.0
Login Register
» Authors » Nelson L Michael

Nelson L Michael

Explore the profile of Nelson L Michael including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 377
Citations 17291
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Merlin L Robb
Jerome H Kim
Sodsai Tovanabutra
Sorachai Nitayaphan
Robert J OConnell
Supachai Rerks-Ngarm
Punnee Pitisuttithum
Eric Sanders-Buell
Michael A Eller
Jaranit Kaewkungwal
Published In
PLoS One
J Virol
PLoS Pathog
AIDS Res Hum Retroviruses
J Acquir Immune Defic Syndr
Affiliations
Soon will be listed here.
Recent Articles
11.
Impact of HLA class I functional divergence on HIV control
Viard M, OhUigin C, Yuki Y, Bashirova A, Collins D, Urbach J, et al.
Science . 2024 Jan; 383(6680):319-325. PMID: 38236978
Heterozygosity of () class I genes is linked to beneficial outcomes after HIV infection, presumably through greater breadth of HIV epitope presentation and cytotoxic T cell response. Distinct allotype pairs,...
12.
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
Sankhala R, Lal K, Jensen J, Dussupt V, Mendez-Rivera L, Bai H, et al.
Nat Commun . 2024 Jan; 15(1):200. PMID: 38172512
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine-elicited antibodies highlights the need to develop next-generation vaccine candidates that confer broad protection. Here we describe...
13.
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
Sankhala R, Dussupt V, Chen W, Bai H, Martinez E, Jensen J, et al.
Structure . 2023 Dec; 32(2):131-147.e7. PMID: 38157856
Given the continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved epitopes on the spike (S) glycoprotein have therapeutic advantages. Here,...
14.
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study
Marichannegowda M, Zemil M, Wieczorek L, Sanders-Buell E, Bose M, OSullivan A, et al.
EBioMedicine . 2023 Nov; 98:104867. PMID: 37939456
Background: The CCR5 (R5) to CXCR4 (X4) coreceptor switch in natural HIV-1 infection is associated with faster progression to AIDS, but the mechanisms remain unclear. The difficulty in elucidating the...
15.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
EClinicalMedicine . 2023 Nov; 64:102168. PMID: 37936652
Background: The literature on first generation COVID-19 vaccines show they were less effective against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and BA.5 subvariants). New vaccines developed...
16.
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine
Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Curtis D, et al.
EBioMedicine . 2023 Oct; 97:104815. PMID: 37793212
Background: Complex patterns of cross-reactivity exist between flaviviruses, yet there is no precise understanding of how sequential exposures due to flavivirus infections or vaccinations impact subsequent antibody responses. Methods: We...
17.
Transmission of highly virulent CXCR4 tropic HIV-1 through the mucosal route in an individual with a wild-type CCR5 genotype
Marichannegowda M, Setua S, Bose M, Sanders-Buell E, King D, Zemil M, et al.
bioRxiv . 2023 Sep; PMID: 37745406
Nearly all transmitted/founder (T/F) HIV-1 are CCR5 (R5)-tropic. While previous evidence suggested that CXCR4 (X4)-tropic HIV-1 are transmissible, detection was not at the earliest stages of acute infection. Here, we...
18.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M, et al.
Lancet Respir Med . 2023 Sep; 11(11):975-990. PMID: 37716365
Background: COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed to describe the clinical efficacy and safety...
19.
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
Sankhala R, Dussupt V, Donofrio G, Gromowski G, De La Barrera R, Larocca R, et al.
Cell Rep . 2023 Aug; 42(8):112942. PMID: 37561630
Zika virus (ZIKV) is an emerging pathogen that causes devastating congenital defects. The overlapping epidemiology and immunologic cross-reactivity between ZIKV and dengue virus (DENV) pose complex challenges to vaccine design,...
20.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study
de Bruyn G, Wang J, Purvis A, Ruiz M, Adhikarla H, Alvi S, et al.
EClinicalMedicine . 2023 Aug; 62:102109. PMID: 37533419
Background: In a parallel-group, international, phase 3 study (ClinicalTrials.govNCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). Methods: Adults, previously...